101 research outputs found

    Two classes of reducible cyclic codes with large minimum symbol-pair distances

    Full text link
    The high-density data storage technology aims to design high-capacity storage at a relatively low cost. In order to achieve this goal, symbol-pair codes were proposed by Cassuto and Blaum \cite{CB10,CB11} to handle channels that output pairs of overlapping symbols. Such a channel is called symbol-pair read channel, which introduce new concept called symbol-pair weight and minimum symbol-pair distance. In this paper, we consider the parameters of two classes of reducible cyclic codes under the symbol-pair metric. Based on the theory of cyclotomic numbers and Gaussian period over finite fields, we show the possible symbol-pair weights of these codes. Their minimum symbol-pair distances are twice the minimum Hamming distances under some conditions. Moreover, we obtain some three symbol-pair weight codes and determine their symbol-pair weight distribution. A class of MDS symbol-pair codes is also established. Among other results, we determine the values of some generalized cyclotomic numbers

    Study on coal mine macro, meso and micro safety management system

    Get PDF
    SummaryIn recent years, the coal mine safety production situation in our country improved year by year, but severe accidents still occurred; the accidents caused great economic loss to the national economy. According to statistical analysis, almost all of the coal mine accidents will expose the hidden danger in before, most of the accidents caused due to safety management not reaching the designated position and the hidden danger management does not take any decision in time. Based on the coal mine safety management holes in our country, the coal mine macro, meso and micro safety management system was established in this paper, which includes meaning and conception of the theories of the macro, meso and micro safety management, and also includes the matching hardware equipment, in order to achieve the hidden danger's closed-loop control and dynamic early warning in the process of coal mine production

    Pancharatnam-Berry Phase Induced Spin-Selective Transmission in Herringbone Dielectric Metamaterials

    Get PDF
    A dielectric metamaterial approach for achieving spin‐selective transmission of electromagnetic waves is proposed. The design is based on spin‐controlled constructive or destructive interference between propagating phase and Pancharatnam–Berry phase. The dielectric metamaterial, consisting of monolithic silicon herringbone structures, exhibits a broadband operation in the terahertz regime

    Hierarchical bismuth vanadate/reduced graphene oxide composite photocatalyst for hydrogen evolution and bisphenol A degradation

    Get PDF
    Bismuth vanadate (BiVO4) is a widely studied photocatalyst for the depollution of contaminated wastewater, production of hydrogen by water splitting, and organic synthesis. The photophysical properties of BiVO4 are sensitive to morphology and quantum confinement effects, and can exhibit enhanced photocatalytic performance in nanocomposites with graphene. Synthesis of hierarchical BiVO4 plates decorated by nanoparticles (h-BiVO4) in contact with reduced graphene oxide (RGO) is reported via a facile one-pot solution phase approach using ethanolamine and a polyethylene glycol stabilizer. The resulting h-BiVO4/RGO photocatalyst exhibited superior photoactivity for bisphenol A (BPA) degradation and hydrogen evolution under visible light irradiation compared to single component h-BiVO4 or a μm-sized block-like BiVO4 morphology. Rates of BPA photocatalytic degradation and apparent quantum efficiency (AQE) decreased in the order h-BiVO4/RGO (4.5 × 10−2 mmol.g−1.min−1; 15.1% AQE) > h-BiVO4 (3.5 × 10−2 mmol.g−1.min−1; 11.7% AQE) > BiVO4 (1 × 10−2 mmol.g−1.min−1; 3.4% AQE), representing a 4.5 fold enhancement for h-BiVO4/RGO versus BiVO4. Liquid phase photodegradation products included benzene-1,4-diol, cyclohexa-2,5-diene-1,4-dione and (2Z)-but-2-enedioic acid. The rate of photocatalytic hydrogen production under visible light was 11.5 µmol.g−1.h−1 for h-BiVO4/RGO, ~383.3 times greater than for BiVO4 (0.03µmol.g−1.h−1). The superior photocatalytic performance of h-BiVO4/RGO is largely attributed to its higher surface area, aided by enhanced visible light absorption and charge separation across the semiconductor-RGO interface, which together confer a higher density and lifetime of photoexcited charge carriers

    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    Get PDF
    Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie
    corecore